Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Adma Biologics (ADMA) Amortization of Deferred Charges (2022 - 2023)

Adma Biologics' Amortization of Deferred Charges history spans 3 years, with the latest figure at $877000.0 for Q4 2023.

For Q4 2023, Amortization of Deferred Charges fell 9.97% year-over-year to $877000.0; the TTM value through Sep 2024 reached $877000.0, down 77.7%, while the annual FY2023 figure was $3.8 million, 27.95% up from the prior year.
Amortization of Deferred Charges reached $877000.0 in Q4 2023 per ADMA's latest filing, down from $993000.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $1.0 million in Q2 2022 to a low of $877000.0 in Q4 2023.